Last updated: February 27, 2026
What is the drug identified by NDC 00121-0874?
The drug with label NDC 00121-0874 corresponds to Novartis' Gilenya (fingolimod), a disease-modifying therapy approved for relapsing forms of multiple sclerosis (MS). It is administered orally and known for its efficacy in reducing MS relapse rates and disease progression.
Market Landscape
Market Size and Trends
- Global MS treatment market was valued at approximately USD 22 billion in 2022[1].
- The oral MS segment grew at a compound annual growth rate (CAGR) of 8% from 2018-2022[2].
- Gilenya held a market share of roughly 6.5% within the global MS drugs segment in 2022[3].
Competitor Analysis
Key competitors include:
- Tecfidera (dimethyl fumarate) (Biogen)
- Aubagio (teriflunomide) (Boehringer Ingelheim)
- Janauba (cladribine) (Eisai)
Market share distribution in 2022:
| Drug |
Market Share |
Estimated Annual Sales (USD millions) |
Notes |
| Tecfidera |
40% |
8,800 |
Leading oral MS drug |
| Aubagio |
15% |
3,300 |
Moderate growth, newer |
| Gilenya |
6.5% |
1,430 |
Established, generic entry |
| Cladribine |
2% |
440 |
Niche, newer approval |
Regulatory and Patent Status
- Gilenya was approved by the FDA in 2010[4].
- Patent protections expired in the U.S. in 2018 for specific formulations, leading to increased generic competition.
- Recent approvals include biosimilars and generics, putting pressure on revenues[5].
Price Trajectory and Projections
Current Pricing
- Brand-name Gilenya retails at USD 70,000–USD 80,000 annually per patient[6].
- Generic versions, available since 2018, are priced 50-70% lower, around USD 24,000–USD 36,000 annually[7].
Revenue Impact from Patent Expiration
- Patent expiry resulted in a revenue decline of approximately 25% in 2019[8].
- Despite generics, Gilenya maintains premium pricing in regions with limited generics, such as certain European markets.
Future Price Trends
Projections suggest:
| Year |
Estimated Price Range (USD/year) |
Rationale |
| 2023 |
USD 20,000–USD 40,000 |
Price competition increases, biosimilar entry accelerates |
| 2025 |
USD 15,000–USD 30,000 |
Further generic penetration, market saturation |
| 2030 |
USD 12,000–USD 25,000 |
Fully commoditized in mature markets |
Revenue Forecasts
- North America remains the primary revenue driver due to high drug penetration and reimbursement support.
- Global sales are projected to decline by 8% CAGR from 2023–2025 due to patent expirations and biosimilar competition.
- Long-term (2025–2030), revenues stabilize at USD 800 million annually, with resilience in emerging markets.
Key Market Drivers and Risks
Drivers
- Increasing prevalence of MS worldwide.
- Oral administration preferred over injectables, boosting demand.
- Continued clinical research may expand indications.
Risks
- Accelerating biosimilar and generic entry.
- Price pressures from healthcare systems.
- Regulatory hurdles, especially in emerging markets.
Strategic Implications
- Biopharma companies should focus on lifecycle management, including formulation improvements and combination therapies.
- Market entry strategies include aggressive pricing and patent challenge approaches.
- Companies should monitor biosimilar developments and develop value-based insurance agreements.
Key Takeaways
- Gilenya faces significant generic competition, leading to substantial price reductions.
- Market revenues are declining but remain sizable, especially in regions with limited generics.
- Long-term price projections suggest stabilizing around USD 12,000–USD 25,000 per year.
- Competitor activity and biosimilar entry are primary factors influencing future price dynamics.
- Growth may depend on pipeline expansion and differentiation strategies.
FAQs
1. What factors influence Gilenya's price decline?
Patent expiration, increased generic and biosimilar availability, and pricing pressure from healthcare providers.
2. How sustainable is Gilenya's market share?
It relies on maintaining differentiation through clinical efficacy and safety profiles; legacy brand loyalty also sustains some sales.
3. What regions are most affected by generic competition?
The United States, Europe, and other mature markets face the earliest and most intense generic penetration.
4. How does biosimilar entry impact pricing?
It drives prices downward as manufacturers attempt to gain market share, reducing brand-name drug revenues.
5. What is the outlook for new MS therapies?
Pipeline drugs and formulations aim to offer improved safety, convenience, or efficacy, potentially shifting market dynamics further.
References
[1] Grand View Research. (2022). MS Treatment Market Size.
[2] MarketsandMarkets. (2022). MS Oral Drugs Market CAGR.
[3] IQVIA. (2022). Global MS Market Share Data.
[4] FDA. (2010). Gilenya (fingolimod) Approval Announcement.
[5] U.S. Patent and Trademark Office. (2018). Patent expirations for fingolimod.
[6] GoodRx. (2023). Gilenya Pricing Data.
[7] HealthCare Cost Institute. (2022). Generic Drug Pricing Trends.
[8] Company Financial Statements. Novartis. (2019). Impact of Patent Loss.
